Loading
A phase 1/2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04925479 by Novartis Pharmaceuticals, with 34 participants planned, started 2021-12-27 and due to reach its primary completion in 2027-09-21. Interventions recorded: Asciminib Pediatric formulation group and Asciminib Adult formulation group.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML), Novartis and the tag pipeline.
Shares Asciminib, Chronic myeloid leukaemia, chronic phase, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.